1600 search results for: phd

Like the pharmaceutical industry as a whole, the market research and business intelligence functions within have experienced a tremendous...

New product launches, product acquisitions, and life-cycle management strategies for existing products (e.g., expansion into related indication)...

Diabetic macular edema (DME) occurs in patients with diabetes as a consequence of diabetic retinopathy and is typically referred to as the leading...

Diabetic retinopathy (DR) occurs as a consequence of diabetes and is the leading cause of visual impairment and blindness among the working-age...

The migraine market stands at the brink of transformation. In the much talked about prevention space, three anti-CGRP MAbs—Aimovig, Ajovy, and...

Only a few weeks ago, in our blog on Stryker’s acquisition of K2M, we wondered whether Mazor Robotics would ever make an appearance in M&A...

What are the most important factors to consider when forecasting the launch of generic Xeljanz? Pfizer’s Xeljanz was the first Janus kinase (Jak...

Stryker’s acquisition of K2M is consistent with the company’s recent M&A track record. With acquisitions of Entellus Medical, Novadaq, and...

Abicipar Pegol Is Non-Inferior to Lucentis With Less-Frequent Dosing in Wet AMD, But May Have Safety Concerns. What Does This Mean for Wet AMD?...

JAK Inhibitors and Biosimilars The 19th Annual European League Against Rheumatism (EULAR) congress concluded its four-day event on June 16, 2018 in...

An Examination of Patient Data in Japan The transformation of treatment paradigms in oncology continues unabated as the last two decades saw an...

Over the last two decades, the treatment paradigm for many cancer indications has been transformed beyond recognition. To fully appreciate the...

At the end of January 2018, the European Commission released a legislative proposal for ratification by the European Parliament and Council aimed...

Roche/Genentech’s lampalizumab fails Phase III development for geographic atrophy Genentech reported on November 9, 2017 that lampalizumab failed...

Lessons from the RA market (claims data analysis) The second half of 2017 has seen FDA approvals of two intravenous (IV) therapies, i.e., BMS’s...

The DRG family is coming to terms this month with the loss of one of its most beloved and influential leaders. Sarah W. Fuller, who co-founded...

ITCA-650, a subdermal osmotic implant that provides continuous delivery of exenatide, is being developed by Intarcia Therapeutics for the treatment...

Patients with osteoporosis are at increased risk of suffering fractures due to a loss in bone strength. These fractures place a considerable burden...

For health exchanges, stability has swung around the markets like a pendulum. At first, drastic problems with Healthcare.gov affirmed the decision...

President Donald Trump and the Republicans took a beating in the November 2017 elections, and healthcare was at the forefront. Democrats were...